Thyrocare Technologies Limited — PPTs, 07-05-2026: Investor Presentation

Thyrocare delivered a solid Q4FY26 with consolidated revenue up 20% YoY to ₹224 Cr and PAT soaring 128% YoY to ₹48.7 Cr. For the full FY26, revenue grew 21% YoY to ₹829 Cr, and PAT jumped 81% YoY to ₹162.85 Cr. EBITDA for FY26 was up 38% YoY to ₹262 Cr. Growth was primarily fueled by the pathology segment, with a 22% YoY revenue increase for FY26, driven by strong partnership (+32%) and franchisee (+18%) performance. The company processed 209.6 million tests and served 19.2 million patients in FY26.

Key developments include onboarding Madhuri Dixit as brand ambassador and expanding the test menu to 1,275 offerings with new technologies. Thyrocare also opened a new Gwalior lab, enhancing its 40-lab India network, alongside its international lab in Tanzania. The company maintains its position as India’s first diagnostic chain with 100% NABL accreditation across all labs.

Going forward, Thyrocare aims to deepen its presence in India with a focused test menu, strengthen its franchise network, and expand partnerships (e.g., insurance, ECG at home). International growth in Tanzania is also a strategic focus. The company's vision remains to make quality diagnostics affordable to all through its B2B service model.